Citadel Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-10,700
Closed -$49K 10295
2019
Q1
$49K Sell
10,700
-800
-7% -$3.79K ﹤0.01% 8829
2018
Q4
$40K Sell
11,500
-7,400
-39% -$51.4K ﹤0.01% 8545
2018
Q3
$191K Sell
18,900
-56,400
-75% -$450K ﹤0.01% 8243
2018
Q2
$545K Buy
75,300
+1,600
+2% +$11.2K ﹤0.01% 6229
2018
Q1
$445K Buy
73,700
+26,900
+57% +$222K ﹤0.01% 6096
2017
Q4
$450K Buy
46,800
+7,900
+20% +$51.7K ﹤0.01% 5805
2017
Q3
$345K Buy
38,900
+20,900
+116% +$216K ﹤0.01% 5856
2017
Q2
$228K Sell
18,000
-44,400
-71% -$525K ﹤0.01% 6365
2017
Q1
$656K Sell
62,400
-41,400
-40% -$441K ﹤0.01% 4620
2016
Q4
$955K Buy
103,800
+5,900
+6% +$66.7K ﹤0.01% 3918
2016
Q3
$1.15M Buy
97,900
+58,100
+146% +$883K ﹤0.01% 3647
2016
Q2
$515K Sell
39,800
-53,800
-57% -$784K ﹤0.01% 4441
2016
Q1
$1.5M Buy
93,600
+39,900
+74% +$758K ﹤0.01% 2989
2015
Q4
$1.54M Buy
53,700
+31,200
+139% +$864K ﹤0.01% 3045
2015
Q3
$640K Sell
22,500
-23,700
-51% -$872K ﹤0.01% 4435
2015
Q2
$1.66M Sell
46,200
-2,200
-5% -$68.5K ﹤0.01% 3281
2015
Q1
$1.41M Sell
48,400
-31,200
-39% -$825K ﹤0.01% 3514
2014
Q4
$1.68M Sell
79,600
-25,800
-24% -$510K ﹤0.01% 3129
2014
Q3
$2.04M Buy
105,400
+87,200
+479% +$1.37M ﹤0.01% 2822
2014
Q2
$284K Buy
+18,200
New +$294K ﹤0.01% 5129

Other funds holding INSY

Citadel Advisors's INSY Position: Q2 2019 in Review

Citadel Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q2 2019, closing a stake of 101,329 shares — an estimated $468K sold.

Citadel Advisors first reported a position in INSY in Q3 2013 and held it in 18 quarters. The position peaked at $27.5M in Q3 2015. 16 funds tracked by Wall St. Rank hold INSY as of Q2 2019.

  • Citadel Advisors reported no remaining Insys Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Citadel Advisors sold 101,329 Insys Therapeutics, Inc. shares in Q2 2019, an estimated $468K.
  • Citadel Advisors first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 18 quarters.
  • Citadel Advisors's Insys Therapeutics, Inc. position peaked at $27.5M in Q3 2015.
  • 16 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2019.

Based on Citadel Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.